A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Langerhans cell histiocytosis; Medulloblastoma; Neuroblastoma; Retinoblastoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Accural started at in July 2017 and 26 patients were enrolled up to July 2018, Scheduled recruitment period is 18 months as per trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology.